Search
ASCO 2026: Allogene announced a CEO succession plan late last week. The two leaders behind it discuss why now is the right time, and update us on the progress of the company's programs
Current CEO David Chang describes why now was the right time to pass the baton to Zach Roberts, and why they are both excited about the company's 1L large B-cell lymphoma program, and learnings on why they believe using a combo approach of CD19 and CD70 is an effective way to go about allogeneic therapy in the future.
May 31
ASCO 2025: Allogene presented data today for a CD70 targeting allogeneic CAR-T against renal cell carcinoma, with a 31% response rate
CEO David Chang describes the data and explains why he believes the company's "Dagger" platform makes a difference. Plus, an update on...
Jun 2, 2025
Making the case for allo durability at #ASCO23 with Allogene’s CEO
Allogene CEO David Chang describes the data his company presented at ASCO on Saturday and makes the case for the durability of the response.
Jun 4, 2023
.png){kind=logo}
